Back

Sequential Activation of Senescence and Apoptosis by ONG41008 Eliminated the Human Pancreatic Ductile Adenocarcinoma in nude mice and xenografted human lung cancer

Youn, B.-S.; Kim, K.; Kim, Y.

2025-06-06 cancer biology
10.1101/2025.06.03.657005 bioRxiv
Show abstract

Current therapeutic limitations associated with pancreatic ductal adenocarcinoma (PDAC) are still evident. We have found that ONG41008, the first human synthetic polyphenol, is able to eradicate PDAC in a nude mouse model. ONG41008 is known to potently attenuate human TGF-{beta} production, inducing both anti-fibrotic capacity and anticancer potential through senescence-coupled apoptosis (SCA). These interesting observations closely paralleled ONG41008s ability to inhibit PDACs, and as expected, ONG41008 alone was able to actually ablate engrafted PDACs in nude mice. Interestingly, the anti-PD 1 developed by MSD did not appear to act on immune activation of exhausted Cd8+ T cells in the tumor microenvironment (TME), but primarily on engrafted PDAC blood vessels. These observations support the latest report from MSD. A549 cells known to be a well appreciated human lung adenocarcinoma cell line were treated with ONG41008. Consistent with the prior observations ONG41008 notably induced SCA. and when A549 cells were xenografted into mice daunting tumor formations were noticed. Upon stimulation with ONG41008 via direct intramural injection of these tumors tumor volumes were rapidly regressed. Taken together, we believe that ONG41008 could be a multifaceted anti-cancer agent not only against PDAC but also against other aggressive cancers such as lung cancer.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
PLOS ONE
5266 papers in training set
Top 9%
19.0%
2
Pharmaceuticals
34 papers in training set
Top 0.1%
8.1%
3
Scientific Reports
3612 papers in training set
Top 9%
6.9%
4
Aging
75 papers in training set
Top 0.2%
6.4%
5
Frontiers in Oncology
103 papers in training set
Top 0.4%
6.4%
6
International Journal of Molecular Sciences
494 papers in training set
Top 1%
5.3%
50% of probability mass above
7
Life Sciences
27 papers in training set
Top 0.2%
3.3%
8
Translational Oncology
21 papers in training set
Top 0.2%
2.5%
9
Biomedicines
67 papers in training set
Top 0.7%
2.2%
10
Journal of Translational Medicine
57 papers in training set
Top 0.5%
2.2%
11
Frontiers in Pharmacology
111 papers in training set
Top 1%
1.8%
12
Heliyon
152 papers in training set
Top 4%
1.5%
13
Cell Death Discovery
58 papers in training set
Top 0.7%
1.5%
14
Biochemistry and Biophysics Reports
30 papers in training set
Top 0.5%
1.4%
15
Molecules
39 papers in training set
Top 0.8%
1.4%
16
Cancers
213 papers in training set
Top 3%
1.4%
17
Frontiers in Medicine
120 papers in training set
Top 3%
1.1%
18
PeerJ
308 papers in training set
Top 9%
1.0%
19
eLife
5828 papers in training set
Top 62%
0.9%
20
Biochemical Pharmacology
20 papers in training set
Top 0.4%
0.9%
21
European Journal of Pharmacology
15 papers in training set
Top 0.5%
0.9%
22
Biomedicine & Pharmacotherapy
42 papers in training set
Top 1%
0.9%
23
iScience
1154 papers in training set
Top 38%
0.6%
24
Frontiers in Immunology
638 papers in training set
Top 10%
0.6%
25
Cells
249 papers in training set
Top 8%
0.6%